EP2146576A4 - Traitement du syndrome de down au moyen d'antagonistes des récepteurs des benzodiazépines - Google Patents

Traitement du syndrome de down au moyen d'antagonistes des récepteurs des benzodiazépines

Info

Publication number
EP2146576A4
EP2146576A4 EP08745691A EP08745691A EP2146576A4 EP 2146576 A4 EP2146576 A4 EP 2146576A4 EP 08745691 A EP08745691 A EP 08745691A EP 08745691 A EP08745691 A EP 08745691A EP 2146576 A4 EP2146576 A4 EP 2146576A4
Authority
EP
European Patent Office
Prior art keywords
treatment
receptor antagonists
down syndrome
benzodiazepine receptor
benzodiazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08745691A
Other languages
German (de)
English (en)
Other versions
EP2146576A1 (fr
Inventor
Srinivas Rao
Jeffery J Anderson
Jay D Kranzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cypress Bioscience Inc
Original Assignee
Cypress Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cypress Bioscience Inc filed Critical Cypress Bioscience Inc
Publication of EP2146576A1 publication Critical patent/EP2146576A1/fr
Publication of EP2146576A4 publication Critical patent/EP2146576A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP08745691A 2007-04-11 2008-04-11 Traitement du syndrome de down au moyen d'antagonistes des récepteurs des benzodiazépines Withdrawn EP2146576A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91125407P 2007-04-11 2007-04-11
PCT/US2008/060133 WO2008128116A1 (fr) 2007-04-11 2008-04-11 Traitement du syndrome de down au moyen d'antagonistes des récepteurs des benzodiazépines

Publications (2)

Publication Number Publication Date
EP2146576A1 EP2146576A1 (fr) 2010-01-27
EP2146576A4 true EP2146576A4 (fr) 2013-01-16

Family

ID=39864354

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08745691A Withdrawn EP2146576A4 (fr) 2007-04-11 2008-04-11 Traitement du syndrome de down au moyen d'antagonistes des récepteurs des benzodiazépines

Country Status (5)

Country Link
EP (1) EP2146576A4 (fr)
JP (1) JP2010523716A (fr)
AU (1) AU2008240148B2 (fr)
CA (1) CA2683754A1 (fr)
WO (1) WO2008128116A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2827336C (fr) 2011-02-23 2016-01-26 Coeruleus Ltd. Complexes de flumazenil, compositions les comprenant et leurs utilisations
US20220354807A1 (en) * 2019-09-30 2022-11-10 Xiamen University Use of valeric acid derivative in treatment of down's syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297256B1 (en) * 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000887A (es) * 2003-07-25 2006-04-19 Neurogen Corp Imidazo-pirimidinas y triazolo-pirimidinas: ligandos del receptor de benzodiazepina.
EP1937236A2 (fr) * 2005-09-07 2008-07-02 Braincells, Inc. Modulation de la neurogenese par inhibition de la hdac

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297256B1 (en) * 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ABI-DARGHAM A ET AL: "Benzodiazepine receptor antagonists: possible uses in the treatment of neuropsychiatric disorders", CNS DRUGS, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 8, no. 3, 1 January 1997 (1997-01-01), pages 244 - 256, XP008102648, ISSN: 1172-7047, DOI: 10.2165/00023210-199708030-00007 *
AUTA J ET AL: "Comparison of the effects of full and partial allosteric modulators of GABA(A) receptors on complex behavioral processes in monkeys", BEHAVIOURAL PHARMACOLOGY 1995 GB, vol. 6, no. 4, 1995, pages 323 - 332, XP009165353, ISSN: 0955-8810 *
DUKA T ET AL: "HUMAN STUDIES ON THE BENZODIAZEPINE RECEPTOR ANTAGONIST BETA-CARBOLINE ZK 93 426: PRELIMINARY OBSERVATIONS ON PSYCHOTROPIC ACTIVITY", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 93, no. 4, 1 January 1987 (1987-01-01), pages 421 - 427, XP009020183, ISSN: 0033-3158, DOI: 10.1007/BF00207229 *
FERNANDEZ FABIAN ET AL: "Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome.", NATURE NEUROSCIENCE APR 2007, vol. 10, no. 4, April 2007 (2007-04-01), pages 411 - 413, XP002688539, ISSN: 1097-6256 *
GHONEIM M M: "The reversal of benzodiazepine-induced amnesia by flumazenil: A review", CURRENT THERAPEUTIC RESEARCH - CLINICAL AND EXPERIMENTAL 1992 US, vol. 52, no. 5, 1992, pages 757 - 767, XP002688538, ISSN: 0011-393X *
KUMAR B A ET AL: "CGS 8216, a benzodiazepine receptor antagonist, enhances learning and memory in mice", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 460, no. 1, 13 September 1988 (1988-09-13), pages 195 - 198, XP024405953, ISSN: 0006-8993, [retrieved on 19880913], DOI: 10.1016/0006-8993(88)91223-1 *
MARCZYNSKI T J ET AL: "Chronic administration of flumazenil increases life span and protects rats from age-related loss of cognitive functions: A benzodiazepine/GABAergic hypothesis of brain aging", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 15, no. 1, 1 January 1994 (1994-01-01), pages 69 - 84, XP024366852, ISSN: 0197-4580, [retrieved on 19940101], DOI: 10.1016/0197-4580(94)90146-5 *
MUMFORD G K ET AL: "Alprazolam and DN-2327 (Pazinaclone) in humans: Psychomotor, memory, subjective, and reinforcing effects", EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY 1995 US, vol. 3, no. 1, 1995, pages 39 - 48, XP009165355, ISSN: 1064-1297 *
NEAVE N ET AL: "Dose-dependent effects of flumazenil on cognition, mood, and cardio-respiratory physiology in healthy volunteers.", BRITISH DENTAL JOURNAL 23 DEC 2000, vol. 189, no. 12, 23 December 2000 (2000-12-23), pages 668 - 674, XP009165311, ISSN: 0007-0610 *
PRATHER P L ET AL: "Learning and memory-enhancing effects of Ro 15-4513: A comparison with flumazenil", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 31, no. 3, 1 March 1992 (1992-03-01), pages 299 - 306, XP025557076, ISSN: 0028-3908, [retrieved on 19920301], DOI: 10.1016/0028-3908(92)90180-W *
SALETU B ET AL: "On the central effects of a new partial benzodiazepine agonist Ro 16-6028 in man: pharmaco-EEG and psychometric studies.", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY, THERAPY, AND TOXICOLOGY FEB 1989, vol. 27, no. 2, February 1989 (1989-02-01), pages 51 - 65, XP009165363, ISSN: 0174-4879 *
See also references of WO2008128116A1 *

Also Published As

Publication number Publication date
JP2010523716A (ja) 2010-07-15
WO2008128116A1 (fr) 2008-10-23
AU2008240148A1 (en) 2008-10-23
CA2683754A1 (fr) 2008-10-23
AU2008240148B2 (en) 2012-09-27
EP2146576A1 (fr) 2010-01-27

Similar Documents

Publication Publication Date Title
HK1244694A1 (zh) 新穎的胰高血糖素受體拮抗劑
IL229507A0 (en) Extrinsic opioid receptor antagonists and their uses
EP2099454A4 (fr) Aminopyrrolidines utilisés en tant qu'antagonistes du récepteur de la chimiokine
IL212551A0 (en) Cxcr4 receptor compounds
EP2184278A4 (fr) Antagoniste de récepteur p2x4
EP2215073A4 (fr) Modulation du sommeil avec des antagonistes du récepteur nr2b
HRP20150661T1 (en) Peripheral opioid receptor and antagonists and uses thereof
PL2137191T3 (pl) Antagoniści obwodowego receptora opioidowego i ich zastosowania
IL209318A0 (en) Bicyclic compounds having activity at the cxcr4 receptor
EP2254413A4 (fr) Antagonistes de récepteurs de cgrp de type imidazobenzazépine
EP2300015A4 (fr) Utilisation d'antagonistes du récepteur gabaa pour traiter une somnolence excessive et des troubles associés à une somnolence excessive
IL205749A0 (en) Modified il-4 mutein receptor antagonists
ZA201008538B (en) Treating psychological conditions using muscarinic receptor m1 antagonists
SI3456340T1 (sl) Antagonisti receptorja za GLP-1 za uporabo pri zdravljenju prirojenega hiperinsulinizma
IL200380A0 (en) Mineralcorticoid receptor antagonists for the treatment of endometriosis
EP2341919A4 (fr) Antagonistes des récepteurs du cgrp
EP2340025A4 (fr) Antagonistes des récepteurs cgrp
ZA200810681B (en) Treating obesity with muscaring receptor mi antagonists
EP2146576A4 (fr) Traitement du syndrome de down au moyen d'antagonistes des récepteurs des benzodiazépines
HK1163571A1 (zh) 用於治療前庭障礙的選擇性組胺 受體拮抗劑
EP2339919A4 (fr) Antagonistes des récepteurs du cgrp à base de dihydroimidazolone bicyclique
EP2273266A4 (fr) Récepteur de parasporine-1 et son utilisation
IL211803A0 (en) Quinazoline derivatives as nk3 receptor antagonists
ZA200906849B (en) Mineralcorticoid receptor antagonists for the treatment of endomertriosis
GB0701632D0 (en) MET receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KRANZLER, JAY, D.

Inventor name: ANDERSON, JEFFERY, J.

Inventor name: RAO, SRINIVAS

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/55 20060101ALI20121206BHEP

Ipc: A61P 25/00 20060101ALI20121206BHEP

Ipc: A61K 31/5517 20060101AFI20121206BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20121218

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130718